Focused On-demand Library for AN1-type zinc finger protein 6

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6FIF0

UPID:

ZFAN6_HUMAN

Alternative names:

Associated with PRK1 protein; Zinc finger A20 domain-containing protein 3

Alternative UPACC:

Q6FIF0; D3DW92; D3DW94; O95792; Q9BQF7; Q9GZY3

Background:

AN1-type zinc finger protein 6, also known as Associated with PRK1 protein and Zinc finger A20 domain-containing protein 3, plays a crucial role in cellular processes. It regulates TNF-alpha induced NF-kappa-B activation and apoptosis, modulates 'Lys-48'-linked polyubiquitination status of TRAF2, and is involved in peroxisomal protein import via interaction with PEX5 and PEX6. Its activity is essential for maintaining cellular homeostasis and responding to stress signals.

Therapeutic significance:

Understanding the role of AN1-type zinc finger protein 6 could open doors to potential therapeutic strategies. Its involvement in NF-kappa-B activation, apoptosis, and protein import into peroxisomes highlights its importance in cellular regulation and stress response, making it a potential target for drug discovery efforts aimed at treating diseases linked to these pathways.